RxDoctor Payments DataLook up a doctor →

Sassan Kaveh, MD

Internal Medicine · Las Vegas, NVNPI 1851385447

Payments from drug & device makers

$22,644in general payments, 2019–2025

Across 404 payments — averaging $56.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lumenis BE Inc$11K
  • AstraZeneca$2K
  • Novo Nordisk$1K
  • Paratek Pharmaceuticals, Inc.$1K
  • AbbVie$967
  • Amarin Pharma, Inc.$680
  • plus $6K from 35 others

What the payments were for

  • Food & beverage$22,26698%
  • Education$3782%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,644 in reported general payments places this provider in the 95th percentile of 1,071 internal medicine providers in Nevada.

See all internal medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$515,294
Medicare patients
180
Services billed
6,520

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide121$132,251
MounjaroTirzepatide68$81,515
JardianceEmpagliflozin52$63,186
EliquisApixaban62$52,515
Tresiba Flextouch U-200Insulin Degludec44$49,612
FarxigaDapagliflozin Propanediol33$32,996
KerendiaFinerenone20$27,468
MyrbetriqMirabegron30$23,982
Fiasp FlextouchInsulin Aspart (Niacinamide)17$18,017
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$11,428
EdarbyclorAzilsartan Med/Chlorthalidone21$9,357
LinzessLinaclotide14$7,338
VascepaIcosapent Ethyl14$6,246
Arnuity ElliptaFluticasone Furoate13$5,487
Atorvastatin Calcium194$4,071

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,328$132,251121 claims
Lilly USA, LLCMounjaro$327$81,51568 claims
Boehringer IngelheimJardiance$643$63,18652 claims
PfizerEliquis$205$52,51562 claims
AstraZenecaFarxiga$2,049$32,99633 claims
BayerKerendia$329$27,46820 claims
Astellas Pharma US IncMyrbetriq$420$23,98230 claims
GSKTrelegy Ellipta, Arnuity Ellipta$329$16,91627 claims
Arbor Pharmaceuticals, Inc.Edarbyclor$255$9,35721 claims
AbbVieLinzess$967$7,33814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,071 internal medicine providers in Nevada.

Other internal medicine in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →